Literature DB >> 25761319

Learn more to do better... even for participants in haemophilia clinical trials.

Antonio Coppola1, Massimo Franchini2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25761319      PMCID： PMC4385062          DOI： 10.2450/2014.0298-14

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  11 in total

1.  The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Authors:  Charles R M Hay; Donna M DiMichele
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

2.  Guidelines for the management of hemophilia.

Authors:  A Srivastava; A K Brewer; E P Mauser-Bunschoten; N S Key; S Kitchen; A Llinas; C A Ludlam; J N Mahlangu; K Mulder; M C Poon; A Street
Journal:  Haemophilia       Date:  2012-07-06       Impact factor: 4.287

3.  Challenges of rare disease research: limited patients and competing priorities.

Authors:  M V Ragni; C G Moore; V Bias; N S Key; P A Kouides; C W Francis
Journal:  Haemophilia       Date:  2011-09-13       Impact factor: 4.287

Review 4.  The modern treatment of haemophilia: a narrative review.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

Review 5.  Future of coagulation factor replacement therapy.

Authors:  F Peyvandi; I Garagiola; S Seregni
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

6.  Mortality and causes of death in Italian persons with haemophilia, 1990-2007.

Authors:  A Tagliaferri; G F Rivolta; A Iorio; E Oliovecchio; M E Mancuso; M Morfini; A Rocino; M G Mazzucconi; M Franchini; N Ciavarella; A Scaraggi; L Valdrè; G Tagariello; P Radossi; G Muleo; P G Iannaccaro; C Biasoli; D Vincenzi; M L Serino; S Linari; C Molinari; E Boeri; M La Pecorella; M T Carloni; E Santagostino; G Di Minno; A Coppola; A Rocino; E Zanon; L Spiezia; C Di Perna; M Marchesini; M Marcucci; A Dragani; S Macchi; P Albertini; M D'Incà; C Santoro; F Biondo; G Piseddu; G Rossetti; G Barillari; G Gandini; A C Giuffrida; G Castaman
Journal:  Haemophilia       Date:  2010-02-09       Impact factor: 4.287

7.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Elaine B Hoffman; Naveen Deenadayalu; Michael D Ezekowitz; A John Camm; Jeffrey I Weitz; Basil S Lewis; Alexander Parkhomenko; Takeshi Yamashita; Elliott M Antman
Journal:  Lancet       Date:  2013-12-04       Impact factor: 79.321

8.  Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.

Authors:  Jerry Powell; Uri Martinowitz; Jerzy Windyga; Giovanni Di Minno; Andrzej Hellmann; Ingrid Pabinger; Monika Maas Enriquez; Lawrence Schwartz; Jørgen Ingerslev
Journal:  Thromb Haemost       Date:  2012-09-26       Impact factor: 5.249

9.  A study of variations in the reported haemophilia A prevalence around the world.

Authors:  J S Stonebraker; P H B Bolton-Maggs; J Michael Soucie; I Walker; M Brooker
Journal:  Haemophilia       Date:  2009-10-21       Impact factor: 4.287

10.  Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.

Authors:  S R Lentz; M Misgav; M Ozelo; S Z Salek; D Veljkovic; M Recht; M Cerqueira; A Tiede; B Brand; M E Mancuso; S Seremetis; A Lindblom; U Martinowitz
Journal:  Haemophilia       Date:  2013-05-07       Impact factor: 4.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.